血脑屏障
P-糖蛋白
药物发现
药品
体内
药理学
药代动力学
干细胞
运输机
药物开发
药物输送
生物
抗药性
计算生物学
多重耐药
生物信息学
化学
神经科学
中枢神经系统
生物技术
细胞生物学
基因
生物化学
有机化学
微生物学
作者
Sezin Aday,Roméo Cecchelli,Dorothée Hallier-Vanuxeem,Marie‐Pierre Dehouck,Lino Ferreira
标识
DOI:10.1016/j.tibtech.2016.01.001
摘要
The development of novel neuropharmaceuticals requires the evaluation of blood-brain barrier (BBB) permeability and toxicity. Recent studies have highlighted differences in the BBB among different species, with the most important differences involving the expression of P-glycoprotein (P-gp), multidrug resistance-associated proteins, transporters, and claudins. In addition, functional studies have shown that brain pharmacokinetics of P-glycoprotein substrates are different in humans and rodents. Therefore, human BBB models may be an important platform for initial drug screening before in vivo studies. This strategy might help to reduce costs in drug development and failures in clinical studies. We review the differences in the BBB among species, recent advances in the generation of human BBB models, and their applications in drug discovery and delivery.
科研通智能强力驱动
Strongly Powered by AbleSci AI